Showing results (171-180 of 385) with videos related to
Sort By:
Pageof 39
Clinical Genitourinary Cancer|February 13, 2022
Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer PatientsRenu Jeyapala, Shivani Kamdar, Ekaterina Olkhov-Mitsel, et al.BJU International|October 13, 2009
'Prostatic evasive anterior tumours': the role of magnetic resonance imagingNathan Lawrentschuk, Masoom A Haider, Nikhil Daljeet, et al.The Journal of Urology|March 26, 2002
Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progressionRichard Choo, Laurence Klotz, Cyril Danjoux, et al.Cancer Prevention Research (Philadelphia, Pa.)|March 19, 2013
Tumor suppressor microRNAs, miR-100 and -125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissueAngeline A Giangreco, Avani Vaishnav, Dennis Wagner, et al.BJU International|May 4, 2012
Does patient age affect survival after radical cystectomy?David Horovitz, Polat Turker, Peter J Bostrom, et al.The Journal of Urology|July 12, 2005
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control studyJacek A Kopec, Vivek Goel, Peter S Bunting, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical ProstatectomyRashid K Sayyid, Andrew Evans, Karen Hersey, et al.Prostate Cancer and Prostatic Diseases|June 8, 2018
Statin use and time to progression in men on active surveillance for prostate cancerViranda H Jayalath, Madhur Nayan, Antonio Finelli, et al.The Journal of Urology|September 18, 2009
A framework for the identification of men at increased risk for prostate cancerMonique J Roobol, Fritz H Schröder, E David Crawford, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 28, 2020
First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single PatientsVikas Prasad, Friedemann Zengerling, Jochen P Steinacker, et al.Pageof 39